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Summary The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats. D-Trp6-LH-RH microcap-
sules were injected once a month for 3 months, in a dose calculated to release 25 jg day- . Control animals received the injection vehicle. Sixty days after the first injection of microcapsules, cyclophosphamide was given
at a loading dose of 50mgkg-' followed by 5 mg kg-' day-' for 30 days, while the treatment with D-Trp6-LH-RH was continued. When the ovaries were examined 3 months and 5 months after discontinuation
of treatment, a significant reduction in the total number of follicles (P<0.01) was found in non-pretreated
animals given cyclophosphamide. This reduction affected mainly follicles larger than 100 .tm. An irreversible disintegration and destruction of granulosa cells was also observed in this group. In animals pretreated with D-Trp6-LH-RH, administration of cyclophosphamide caused no reduction in the number and diameter of follicles. Thus, the treatment with D-Trp6-LH-RH microcapsules before and during chemotherapy prevented
the ovarian injury inflicted by cyclophosphamide. The suppression of gonadal function by LH-RH analogues could be possibly utilised for the protection of the ovaries against damage caused by cytotoxic drugs.
The administration of cytotoxic drugs such as cyclophos-
phamide, chlorambucil, vincristine, procarbazine, busulphan
and others may cause amenorrhoea in women and inhibit
spermatogenesis in men (Damewood & Grochow, 1986;
Gradisher & Schilsky, 1988; Rivkees & Crawford, 1988).
These agents are commonly used in the treatment of malig-
nant diseases such as Hodgkin's disease and leukaemia.
Cyclophosphamide has been likewise used in the treatment of
nephrotic syndrome, various forms ofglomerulonephritis and
connective tissue diseases and for the control of organ rejec-
tion after transplantation (Gradishar & Schilsky, 1988).
Samaan et al. (1978) also reported that amenorrhoea that
developed in 70% of premenopausal patients with breast
cancer after adjuvant chemoimmunotherapy consisting of 5-
fluorouracil, adriamycin, cyclophosphamide and BCG was a
result of primary ovarian failure. Frequently, cytotoxic
therapy has to be used in young people in whom the preser-
vation of gonadal function and fertility is important.
The incidence of gonadal dysfunction in patients treated
with cytotoxic drugs varies according to pubertal state, sex,
and type of chemotherapeutic regimen. Patients treated dur-
ing adulthood have the highest incidence of gonadal dysfunc-
tion, whereas subjects treated during the prepubertal stage
are less affected by chemotherapy (Damewood & Grochow,
1986; Rivkees & Crawford, 1988).
Since cytotoxic drugs affect more tissues with a rapid
cellular turnover, it has been suggested that a state of
induced gonadal inhibition during the exposure to
chemotherapy may protect the gonads (Karashima et al.,
1988; Rivkees & Crawford, 1988). Chronic administration of
agonists of luteinising hormone releasing hormone (LH-RH),
after an initial period of stimulation, induces down-
regulation of the receptors, desensitisation of pituitary
gonadotrophs and suppression of the gonadal functions
(Schally et al., 1980; Schally, 1989). This inhibitory effect is
reversible, and gonadal recovery occurs after treatment with
LH-RH agonists is discontinued. This approach has been
suggested as a possible protective method against gonadal
damage induced by chemotherapeutic drugs and radiation
(Glode et al., 1982; Jarrel et al., 1987b; Karashima et al.,
1988; Lewis et al., 1985; Schally et al., 1987; Schally, 1989).
Recently, we have developed long-acting delivery systems of
D-Trp6-LH-RH (Schally, 1989; Mason-Garcia et al., 1985). Microcapsule or microparticle formulations release
therapeutic concentrations of this analog for 30 days or
longer after intramuscular injection (Bokser et al., 1989; Mason-Garcia et al., 1985). This continuous-release formula-
tion of LH-RH agonists is much more efficacious than daily injections (Bokser et al., 1989).
Testes show a higher incidence of chemotherapy-induced
damage (Rivkees & Crawford, 1988; Wang et al., 1980). However, the incidence of ovarian dysfunction after
chemotherapy can reach 80% among women treated for
Hodgkin's disease (Chapman et al., 1979). Several studies on
gonadal protection against the damage induced by cytotoxic
drugs have been performed in males of different species (Glode et al., 1982; Karashima et al., 1988; Lewis et al.,
1985; Nseyo et al., 1985), but the information about females
is limited. Ataya et al. (1985) reported that administration of
the LH-RH agonist D-Leu6-des-Gly'0-NH2-LH-RH ethyl- amide before and during chemotherapy was able to prevent the ovarian follicle loss induced by cyclophosphamide in the
rat. The evaluation was performed immediately after the
cessation of cyclophosphamide administration, and women
submitted to chemotherapeutic drugs may progress after
several months or several years from a condition of fertility
and normal menses to sterility and premature menopause
(Chapman et al., 1979). Much additional information is
needed to establish whether LH-RH agonists can prevent the
delayed manifestations of gonadotoxicity and protect the
ovary from injury inflicted by cytotoxic drugs. The aim of
this study was to investigate the effects of the treatment with
microcapsules of the agonist D-Trp-6-LH-RH on the preven- tion of ovarian damage induced by cyclophosphamide. The
ovarian recovery was evaluated after a long-term follow-up.
Materials and methods
Animals
Female Sprague-Dawley rats, weighing 200-250 g, were
used in all experiments. Animals were allowed standard rat
diet and tap water ad libitum, and were maintained under
controlled conditions: 12 h light, 12 h dark schedule at
24 ±20C.
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Drugs
D-Trp6-LH-RH microcapsules consisted of D-Trp6-LH-RH
(2% w/w) distributed within a polymeric matrix of poly
(DL-lactide-co-glycolide) (98%, w/w). For injection, mic-
rocapsules were suspended in 0.7 ml of injection vehicle con-
sisting of 2% CM-cellulose and 1% Tween 80 in water
(Bokser et al., 1989; Mason-Garcia et al., 1985). The suspen-
sion was mixed thoroughly on a vortex mixer and injected
through an 18-gauge needle. Cyclophosphamide (Cytoxan,
Mead Johnson, Evansville, IN, USA) was prepared daily in
sterile 0.9%-saline.
Experimental procedure
Rats were divided into four groups as follows: (1) saline
control (n = 10); (2) D-Trp6-LH-RH microcapsules control
(n = 10); (3) cyclophosphamide control (n = 15); and (4) D-
Trp6-LH-RH plus cyclophosphamide (n = 12). Groups 2 and
4 were injected intramuscularly once a month for 3 months
with D-Trp'-LH-RH microcapsules at a dose of 36 mg cal-
culated to release 25 jig day-' of D-Trp6-LH-RH for 30 days.
Immediately after the third injection of microcapsules,
groups 3 and 4 received a loading dose of 50 mg kg-' of
cyclophosphamide, followed by daily i.p. injections of
5 mg kg-' for 30 days. Group 1 received the microcapsule
vehicle once a month and daily injections of 0.9% saline.
Three and five months after the last injection of cyclophos-
phamide, four to nine animals from each group were killed.
Since most of the rats in the cyclophosphamide treated group
stopped cycling and were in permanent oestrus, all the cycl-
ing animals in other groups were killed on the day of oestrus.
Blood was collected for hormone determination and ovaries
were removed, weighed and prepared for histological
examination.
Histologicalprocedures
The ovaries were fixed in 10% neutral buffered formalin and
embedded into paraplast; 6 lm thick sections were cut and
stained with hematoxylin and eosin. One ovary of each
animal was examined. Every fortieth section was examined
using a light microscope (Leitz Diaplan equipped with a
calibrated ocular micrometre net). Follicles with a nucleolus
in the oocyte were counted. The total number of follicles was
estimated using the method of Dornfeld et al. (1942). The
diameter of the follicles was determined as the mean of the
longest and shortest diameter of each follicle measured as a
straight-line distance between opposite points of the base-
ment membrane. Measurements were carried out with the
ocular micrometre net.
Hormone determination
Serum LH and FSH were determined by specific radioim-
munoassay (RIA) using materials supplied by the National
Hormone and Pituitary Program (NHPP) (Niswender et al.,
1968). Oestradiol was extracted from serum and measured
using a kit provided by Radioassay System Laboratories Inc.
(Carson, CA, USA) (Abraham, 1974). All samples for each
hormone at 3 months and 5 months after discontinuation of
treatment were analysed in the same assays. The intra and
inter-assay coefficient of variation were less than 10% and
15% respectively for these assays. Results are expressed as
mean ± s.e.m.
Statistical significance was assessed by Duncan's new mul-
tiple range test using a computer program (Redding &
Schally, 1983).
Results
Three months after discontinuation of treatment, the rats
receiving cyclophosphamide alone, had lower body weights
than the controls (P<0.01), while the animals treated with
D-Trp6-LH-RH microcapsules or with the combination
showed increases in body weights (P<0.01 and P<0.05
respectively) (Table I). A marked decrease in the ovarian
weight was seen in all of the treated groups (P<0.01) (Table
I). The treatment with cyclophosphamide alone induced a
significant reduction in the total number of follicles (P<0.01)
(Table I). This reduction affected mainly follicles with a
diameter larger than 30 1tm, with an almost complete disap-
pearance of follicles larger than 200 gm (Figure 1). In the
groups receiving microcapsules or the combination, the total
number of follicles was higher than in the controls (P<0.05
and P<0.01 respectively) (Table I). This difference was
mainly due to follicles sized between 100 and 200 gm (Figure
1). In the cyclophosphamide treated group, several follicles
showed an irreversible disintegration and destruction of the
granulosa cells (Figure 2a). Although this phenomenon was
observed also in some of the animals treated with the com-
bination, it was reversible and no damage was found at the
end of the experiment (Figure 2b). In the animals treated
only with cyclophosphamide, the LH serum levels were lower
than in the controls (P<0.01), while the rats treated with the
LH-RH analogue or with the combination showed no differ-
ences with respect to the untreated group. There was no
significant differences in FSH levels between treated and
untreated groups (Table I).
Five months after cessation of treatment, the body weights
of the cyclophosphamide treated animals remained
significantly lower than in controls (P<0.05), while no
differences were observed in the D-Trp6-LH-RH microcap-
sules or in the combination treated groups (Table II). At this
time, the ovarian weights were similar in the four groups.
However, the total number of follicles and the diameter of
follicles in the rats treated only with cytoxan were smaller
(P<0.05 and 0.01, respectively) (Table II). When the number
of follicles was evaluated according to their diameter, the
follicles sized 200 im or larger had virtually disappeared in
the group given cytoxan alone (Figure 3). The number and
diameter of the follicles in the groups given D-Trp6-LH-RH
alone or in combination with cytoxan were similar to those
of controls (Table II).
Cyclophosphamide treated rats showed LH levels lower
than the controls (P<0.01), but the group given microcap-
sules and the combination group showed normal levels.
There were no significant differences in the FSH levels
between treated and untreated groups. In the cyclophos-
phamide treated animals, the oestradiol levels were
significantly lower than in controls (P<0.05) (Table II).
TableI Changesinbodyweight, ovarianweight, thenumberanddiameterofovarian follicles, and LH and
FSH serum levels in conrol and treated rats 3 months after discontinuation of treatment with cytoxan,
D-Trp6-LH-RH and the combination of both drugs
Body Ovary Diameter of
weight weight Number of follicles LH FSH
(g) (mg) follicleSa (AM) (ng ml-') (ng ml-')
Control 337± 11.2 84.2± 3.8 1056±40.0 141.5± 13.7 0.55±0.06 4.9±0.2
Cytoxan 267± 11.8c 57.1 ±3.5c 528± 112C 59.7+7.8b 0.36±0.03c 5.8±0.4
D-Trp6-LH-RH 388 13.9c 50.6 5.5c 1440± 108b 138.2 8.3 0.52± 0.04 5.0±0.2
Combination 377± 11.2b 56.3±8.8c 1692± 124C 134.2±6.2 0.50±0.04 5.2±0.8
Means± s.e.m. aRepresents the mean of the total number and diameter of all the follicles counted.
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Figure 1 Effects of administration ofcyclophosphamide, D-Trp6-
LH-RH and their combination on the size and distribution of
ovarian follicles in rats evaluated 3 months after cessation of
treatment. *P<0.05 and **P<0.01 vs controls; + P<0.05 and
+ + P<0.01 vs combination.
Figure 2 a, Damaged follicles in the ovary of a cyclophos-
phamide treated rat. The granulosa cell layer is thin and desinteg-
rated with cystic changes in the follicles (H&E, x 160). b, Nor-
mal follicles and corpora lutea in the ovary of a rat treated with
both D-Trp6-LH-RH and cyclophosphamide (H&E, x 100).
400 ro Control
cm Cyclophosphamide
350 - D-Trp6-LH-RH microc.
O300 a Combination
300
~250 *
0200-
.150- 4
z 100 *
50 + ++
*
< 30 31-99 100-200 201-300
Diameter of follicles (,um)
> 300
Figure 3 Effects of administration ofcyclophosphamide, D-Trp6-
LH-RH and their combination on the size and distribution of
ovarian follicles in rats evaluated 5 months after cessation of
treatment. *P<0.05 and **P<0.01 vs controls; + P<0.05 and
+ + P<0.01 vs combination.
Discussion
Gonadal damage induced by chemotherapy is a serious long-
term complication, particularly for the younger cancer
patients (Damewood & Grochow, 1986; Gradishar & Schil-
sky, 1988; Rivkees & Crawford, 1988). A concentrated effort
is needed to develop an approach for protecting gonadal
function against the deleterious effects of chemotherapeutic
agents. The availability of superagonists and modern
antagonists of LH-RH may make such an approach possible.
Although several reports have been published about the pro-
tection of spermatogenesis in males of different species based
on the use of LH-RH agonists or sex steroids (Delic et al.,
1986, 1987; Glode et al., 1982; Karashima et al., 1988; Lewis
et al., 1985; Nseyo et al., 1985), such observations in females
are scarce. Chapman and Sutcliffe (1981) found that the
administration of oral contraceptives to women treated with
cytotoxic drugs protected the ovaries against the injury
caused by these agents. However, the use of oestrogen and
progestin in patients submitted to chemotherapy could be
hazardous (Ataya et at., 1985). Recently, Ataya et al. (1985)
reported that the agonist D-Leu6-des-Gly'0NH2-LH-RH
ethylamide prevented the follicular loss produced immed-
iately after the cessation of cyclophosphamide administration
in rats, through the inhibition of the process of recruitment
of small follicles into the pool of larger follicles. The damage
induced by cytotoxic drugs is dependent on chemotherapeutic
regimen and the dose administered (Damewood & Grochow,
1986; Rivkees & Crawford, 1988). It has been reported that
49% of patients treated for Hodgkin's disease became
amenorrhoeic, 34% showed irregular menstrual cycles and
only 17% exhibited a normal ovarian function immediately
after the therapy (Chapman et al., 1979). Moreover, after 16
months of follow-up, 30% or the women with normal and
irregular menstrual cycles showed a progressive loss of
ovarian function (Chapman et al., 1979). This indicates that
Table II Changes in body weight, ovarian weight, number and diameter ofovarian follicles, and LH, FSH and estradiol
serum levels in conrol and treated rats 5 months after discontinuation of treatment with cytoxan, D-Trp6-LH-RH and the
combination of both drugs
Body Ovary Diameter of
weight weight Number of follicles" LH FSH Oestradiol
(g) (mg) follicles" (AJm) (ng ml-') (ng ml-') (pg ml-,)
Control 385±25.0 69.3± 7.7 624±40.1 153.5±23.9 0.59±0.07 5.1 ±0.9 35.4±6.5
Cytoxan 311±14.lb 71.1±6.6 448± 52.6b 76.6± 8.5c 0.36±+0.02b 3.6±0.6 15.2±2.3b
D-Trp6-LH-RH 422±27.6 83.4±9.5 536±76.8 154.4± 15.6 0.53±0.12 4.2±0.5 33.7± 12.1
Combination 342± 10.8 83.3±4.0 632± 16.4 168.2±17.4 0.45±0.05 4.9±1.0 28.6± 1.6
Means±s.e.m. 'Represents the mean ofthe total number and diameter ofall the follicles counted. bp<o.05 vs controls.
CP<0.01 vs controls.
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in addition to an early ovarian damage induced by cytotoxic
agents, there are some delayed effects manifested by pre-
mature menopause and loss of reproductive function. In
the present study we investigated if pretreatment with D-
Trp6-LH-RH microcapsules could protect ovaries against
damage inflicted by cyclophosphamide. Since 3-5 months
after the cessation of the treatment, virtually no medium to
large follicles were observed in the rats treated only with
cyclophosphamide, this suggests that in addition to the
vulnerability of these follicles to the action of cytoxan, there
is a critical sensitive period in which the follicular develop-
ment is irreversibly affected by this chemotherapeutic agent.
It is probable that the inhibition of some of the processes
involved in the follicular proliferation induced by D-Trp6-LH-
RH microcapsules prevented this irreparable damage. The
administration of another LH-RH agonist D-Ser (Bu')6
Azgly'°-LH-RH ethylamide to rats produced inhibition of the
ovarian 3H-thymidine uptake, which is an index of mitotic
ovarian activity (Ataya et al., 1988). The number of
granulosa cells per follicle has been directly correlated with
the follicular diameter (Hirschfield & Midgley, 1978). Our
results show that the animals treated only with cyclophos-
phamide had irreversible destruction and disintegration of
the granulosa cells, while in the group treated with combina-
tion of D-Trp6-LH-RH microcapsules and cyclophosphamide
this damage was reversible. Although these and other results
(Ataya et al., 1985; Glode et al., 1982; Karashima et al.,
1988; Lewis et al., 1985; Nseyo et al., 1985) indicate the
efficacy of LH-RH analogs in protecting the gonads against
the damage produced by cytotoxic drugs, there are some
contradictory reports. It has been stated that the LH-RH
agonist D-Leu6-LH-RH did not protect the testes against the
cytotoxicity of cyclophosphamide in mice (Da Cunha et al.,
1987). Furthermore, the combination of D-Nal (2)6-LH-RH
with cyclophosphamide exacerbated the deleterious effect of
chemotherapy on the testes in dogs (Goodpasture et al.,
1988). Since there is a marked variation between the species
in the degree of inhibition achieved with LH-RH agonists
(Vickery, 1986), the optimal dosage and duration of pre-
treatment with the agonists must be the subject of additional
investigations before any possible clinical trials.
In spite of the evidence of ovarian damage in the group
treated with cyclophosphamide alone, as manifested by
reduction in the ovarian weight, decrease in the number of
follicles and a fall in serum oestradiol, there was no elevation
in serum gonadotrophin levels. Similar results were reported
by Jarrel et al. (1987a). This suggests a possible cytotoxic
effect of cyclophosphamide on the hypothalamo-pituitary
axis leading to a reduction in gonadotrophin secretion.
Weight loss and chronic stress could be also involved in these
phenomena (Frisch & McArther, 1974; Hulse et al., 1982).
Although the initial differentiation of somatic elements into
follicular cells occurs even in the absence of circulating
gonadotrophin, normal development of medium sized to
large follicles depends on gonadotrophic stimulation (Hardy
et al., 1974; Lunenfeld et al., 1975). Interference with the
pituitary secretion could be an additional mechanism respon-
sible for gonadal failure seen in these animals. Since no
alterations were detected in the pituitary-gonadal axis in the
group treated with the combination as compared to controls,
it is feasible that the functional inhibition of the pituitary
gonadotrophs produced by the LH-RH agonist, protects the
hypophyseal cells against a possible damage inflicted by
cyclophosphamide.
As expected, the animals treated with cyclophosphamide
alone showed a marked decrease in their body weight (Ataya
et al., 1985; Jarrel et al., 1987a), while the rats receiving only
D-Trp6-LH-RH exhibited a significant increase, which could
be attributed to the pharmacological castration produced by
the LH-RH agonists (Bokser et al., 1989). The group treated
with the combination also showed an augmentation in the
body weight as compared to controls. This raises an intrigu-
ing possibility that other organs may have been protected
against the toxic effects of cyclophosphamide. However, no
differences were found in peripheral white blood cell count
(WBC) between the groups treated with cyclophosphamide
alone or in combination with D-Trp6-LH-RH, the WBC of
both groups being lower than in untreated controls (data not
shown). This indicates that the analogue was unable to pre-
vent the toxic effects of cyclophosphamide on the bone mar-
row. Ataya et al. (1988) showed that, in contrast to the
ovary, the treatment with an LH-RH agonist did not inhibit
mitotic activity in the duodenum, skeletal muscle or bone
marrow. Further investigations are necessary in order to
evaluate a possible systemic protection against the deleterious
actions of cytotoxic drugs.
It was interesting that 3 months after the treatment, the
groups receiving D-Trp6-LH-RH microcapsules or the com-
bination with cyclophosphamide exhibited a higher number
of follicles per ovary than the control group. Hypophysec-
tomy also retards the rate at which the oocytes disappear
from the ovaries in mice (Jones & Krohn, 1961). This sug-
gests that the inhibition of the gonadotrophin secretion
induced by LH-RH agonists is also able to retard the normal
process of progressive loss of oocytes caused by the natural
mechanism of aging (Ataya et al., 1989).
Whereas repeated administration of LH-RH agonists is
required to reduce the levels of LH, FSH and sex steroids, an
immediate inhibition can be obtained after the first injection
of LH-RH antagonists (Bajusz et al., 1988a, b; Schally et al.,
1980; Schally, 1989; Vickery, 1986). Recently, we have syn-
thesised highly potent antagonists of LH-RH, free of side-
effects in animals and humans (Bajusz et al., 1988a,b;
Gonzalez-Barcena et al., 1989; Schally, 1989). In addition, we
have developed prototypes of sustained delivery systems con-
sisting of microcapsules of our LH-RH antagonist SB-75
(Csernus et al., 1990). Since, in patients afflicted with a
malignant disease, chemotherapy may have to be started
soon after the diagnosis is made, LH-RH antagonists may be
preferred over the agonists for induction of gonadal inhibi-
tion, considering the rapidity of their suppressive action
(Karashima et al., 1988; Schally et al., 1980; Schally, 1989).
The recent clinical availability of highly efficacious sustained
delivery formulations of various LH-RH agonists and the
development of new LH-RH antagonists free of side-effects,
may make possible new approaches for the prevention of
gonadal damage produced in patients subjected to cytotoxic
chemotherapy.
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